ES2172242T3 - Composiciones oftalmicas de liberacion mantenida conteniendo medicamentos solubles en agua. - Google Patents

Composiciones oftalmicas de liberacion mantenida conteniendo medicamentos solubles en agua.

Info

Publication number
ES2172242T3
ES2172242T3 ES98956532T ES98956532T ES2172242T3 ES 2172242 T3 ES2172242 T3 ES 2172242T3 ES 98956532 T ES98956532 T ES 98956532T ES 98956532 T ES98956532 T ES 98956532T ES 2172242 T3 ES2172242 T3 ES 2172242T3
Authority
ES
Spain
Prior art keywords
water soluble
containing water
ophthalmic compositions
release containing
maintenance release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956532T
Other languages
English (en)
Inventor
Lyle M Bowman
James F Pfeiffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25507756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172242(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Application granted granted Critical
Publication of ES2172242T3 publication Critical patent/ES2172242T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición oftálmica que comprende: una cantidad farmacológicamente efectiva de un medicamento oftálmico soluble en agua, alrededor de 0,5 a 2,0% de polímero conteniendo carboxilo reticulado, alrededor de 0,5 a 5,0% de azúcar, y agua; teniendo dicha composición un pH de por lo menos alrededor de 6,7 y una viscosidad de alrededor de 1000 a 5000 cps.
ES98956532T 1997-11-04 1998-11-04 Composiciones oftalmicas de liberacion mantenida conteniendo medicamentos solubles en agua. Expired - Lifetime ES2172242T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/963,815 US6159458A (en) 1997-11-04 1997-11-04 Sustained release ophthalmic compositions containing water soluble medicaments

Publications (1)

Publication Number Publication Date
ES2172242T3 true ES2172242T3 (es) 2002-09-16

Family

ID=25507756

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956532T Expired - Lifetime ES2172242T3 (es) 1997-11-04 1998-11-04 Composiciones oftalmicas de liberacion mantenida conteniendo medicamentos solubles en agua.

Country Status (13)

Country Link
US (1) US6159458A (es)
EP (1) EP1028707B1 (es)
JP (1) JP2001521885A (es)
AT (1) ATE213405T1 (es)
AU (1) AU745339B2 (es)
CA (1) CA2302379A1 (es)
DE (1) DE69803940T2 (es)
DK (1) DK1028707T3 (es)
ES (1) ES2172242T3 (es)
NO (1) NO20001042L (es)
NZ (1) NZ503063A (es)
PT (1) PT1028707E (es)
WO (1) WO1999022713A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6699492B2 (en) * 1999-03-31 2004-03-02 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP2263621B1 (en) 2001-04-07 2015-05-20 Glaukos Corporation System for treating ocular disorders
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
AU2002305400A1 (en) 2001-05-03 2002-11-18 Glaukos Corporation Medical device and methods of use for glaucoma treatment
US7331984B2 (en) 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US7163543B2 (en) 2001-11-08 2007-01-16 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
EP1507513A1 (de) * 2002-05-24 2005-02-23 Dr. GERHARD MANN chem.-pharm. Fabrik GmbH Tropfbares ophthalmisches gelpräparat mit diclofenamid und timolol
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20050209606A1 (en) * 2004-02-26 2005-09-22 Dharmendra Jani Alginate viscoelastic composition, method of use and package
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
CA2615231A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Prevention and treatment of ophthalmic complications of diabetes
CA2633655A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2023721A2 (en) * 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Preparation and utility of substituted erythromycin analogs
US20080021068A1 (en) * 2006-07-24 2008-01-24 Akorn, Inc. Aqueous gel formulation and method for inducing topical anesthesia
AU2007319383A1 (en) 2006-11-10 2008-05-22 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US8778999B2 (en) 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP4289416A3 (en) 2009-05-18 2024-01-03 Dose Medical Corporation Drug eluting ocular implant
JP2011093891A (ja) * 2009-09-30 2011-05-12 Rohto Pharmaceutical Co Ltd 眼科用組成物
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP3659495B1 (en) 2011-09-13 2022-12-14 Dose Medical Corporation Intraocular physiological sensor
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3442479B1 (en) 2016-04-20 2026-03-04 Glaukos Corporation Bioresorbable ocular drug delivery device
WO2018141063A1 (en) 2017-02-02 2018-08-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5209927A (en) * 1985-01-23 1993-05-11 Alcon Laboratories, Inc. Ophthalmic solution
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5075104A (en) * 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
DE4209722C3 (de) * 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure

Also Published As

Publication number Publication date
WO1999022713A1 (en) 1999-05-14
DK1028707T3 (da) 2002-06-17
EP1028707A1 (en) 2000-08-23
NZ503063A (en) 2002-04-26
PT1028707E (pt) 2002-07-31
NO20001042L (no) 2000-05-04
JP2001521885A (ja) 2001-11-13
AU745339B2 (en) 2002-03-21
DE69803940T2 (de) 2002-10-02
US6159458A (en) 2000-12-12
ATE213405T1 (de) 2002-03-15
EP1028707B1 (en) 2002-02-20
AU1303699A (en) 1999-05-24
CA2302379A1 (en) 1999-05-14
DE69803940D1 (de) 2002-03-28
NO20001042D0 (no) 2000-03-01

Similar Documents

Publication Publication Date Title
ES2172242T3 (es) Composiciones oftalmicas de liberacion mantenida conteniendo medicamentos solubles en agua.
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
BR0307893A (pt) Formulação oftálmica com sistema de goma
IL137955A0 (en) Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
FR2705356B1 (fr) Compositions d'adhésif de pression de silicone.
CA2136331A1 (en) New pharmaceutical uses of krill enzymes
AU697005B2 (en) Implantable molded articles for the administration of active substances to plants
EP1167354A3 (en) Racemic huperzine A
AU4627096A (en) Pharmaceutical compositions in the form of slow release tablets based on high molecular weight polysaccharide granules
HUP9801414A2 (hu) Nátrium-alginátot és kálium-bikarbonátot tartalmazó folyékony vizes gyógyszerkészítmények
NO950595D0 (no) Oftalmologisk preparat
EP0651634A1 (en) CROSSLINKED POLYHYDROXYL MATERIAL FOR ENZYMATICALLY CONTROLLED DRUG RELEASE.
PT1007040E (pt) Utilizacao de fanquinona no tratamento da doenca de alzheimer
EP0804923A3 (en) Skin protection, fragrance enhancing and vitamin delivery composition
SE9403905D0 (sv) New formulations
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
ES2134941T3 (es) Pastillas de lactulosa.
WO2001022917A3 (en) Effervescent compositions comprising nimesulide
ITMI922018A0 (it) Bassi polimeri dell'n-vinilpirrolidone monofunzionalizzati ad un estremo per la preparazione di coniugati con enzimi, polipeptidi farmaci
MX9500324A (es) Compuestos farmaceuticos y el uso de los mismos en el tratamiento de enfermedades neurologicas y sus etiologias sintomaticas relacionadas.
IT1304852B1 (it) Miscela di piante medicinali per la prevenzione e la cura delleemorroidi.
CO4340677A1 (es) Formulaciones novedosas conteniendo paroxetina
UA23119A (uk) Психотропhий засіб

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1028707

Country of ref document: ES